R

Revolution Medicines

Clinical-stage oncology company developing RAS inhibitors

Global Development Lead - Global Development Lead, Clinical Development

Clinical Research OperationsConfirmed live in the last 24 hours
Full-timeRedwood City, CA, USA

About the Job

Requirements

  • MD or international equivalent, with board certification in Medical Oncology or Hematology/Oncology; adult solid tumor focus strongly preferred.
  • Recognized expertise in NSCLC developed through academic clinical leadership and/or substantial industry experience.
  • At least 13 years of oncology clinical development experience, or a combination of senior academic clinical leadership and relevant industry roles; academic leadership may count when directly related to oncology trials and patient care.
  • Demonstrated leadership of global, late-stage development programs, including design and execution of pivotal Phase 2/3 studies.
  • Experience owning or leading global regulatory strategy, including direct involvement in multiple interactions with global health authorities.
  • Proven ability to align and influence senior stakeholders across a highly matrixed organization.
  • Ability to communicate complex scientific and clinical concepts clearly to executives, cross-functional partners, and external experts.
  • Skill in navigating conflict, establishing role clarity, and building durable cross-functional trust.
  • Commitment to developing people and building strong, resilient teams.
  • Written and verbal communication skills.
  • Ability to travel approximately 25–30% domestically and internationally.

Responsibilities

  • Own and lead the global clinical development strategy for the assigned program, integrating scientific, clinical, regulatory, biomarker, and commercial considerations.
  • Partner with the Project Team Leader or Lifecycle Team Leader to represent and integrate clinical development strategy, positions, and decision-making into lifecycle planning for the molecule, with alignment on roles, decision rights, and accountability.
  • Develop and maintain the Target Product Profile, Clinical Development Plan, risk assessments, scenario analyses, and long-range program roadmap.
  • Present strategic recommendations to internal governance bodies and drive timely, high-quality program decision-making.
  • Ensure strategy reflects disease-area insight, emerging science, competitive intelligence, and evolving regulatory expectations.
  • Oversee the design, execution, and delivery of pivotal and registration-enabling Phase 2/3 studies, including protocol strategy, enrollment and geographic planning, patient safety oversight, and data interpretation.
  • Ensure alignment and harmonization across related studies and regions to support regulatory and lifecycle objectives.
  • Provide senior clinical leadership across functions to anticipate risks, resolve complex issues, and deliver critical milestones through matrixed teams.
  • Guide regulatory briefing-material preparation and serve as the senior clinical representative in global health-authority interactions.
  • Serve as the program’s senior medical authority, providing expertise in pancreatic and colorectal cancers.
  • Translate scientific, translational, and biomarker insights into actionable clinical strategy.
  • Engage key opinion leaders, investigators, advisory boards, and external experts to refine development strategy and strengthen scientific and clinical positioning.
  • Lead the assigned program’s clinical direction and integrated decision-making across functions.
  • Lead a cross-functional Global Development Team in partnership with the Project Team Leader or Lifecycle Team Leader, providing direction and accountability for outcomes.
  • Lead through influence and authority when program priorities cross functions, senior leaders, and organizational boundaries.
  • Partner with Medical Affairs and Commercial colleagues to align clinical strategy with future market needs.
  • Contribute to broader development-strategy, standards, and best-practices discussions as a senior Clinical Development leader.
  • Lead an established multidisciplinary Clinical Development Team, including multiple senior direct reports, with accountability for alignment, performance, and program delivery.
  • Assess team capabilities, clarify roles and decision rights, and establish operating cadence for execution during late-stage development.
  • Lead teams through transitions, inflection points, or accelerated timelines.
  • Mentor senior clinical development staff and contribute to organizational capability-building.
  • Model the company’s values of scientific rigor, transparency, inclusiveness, and commitment to patients.
  • Contribute to the evolution of development processes, tools, and governance practices to improve efficiency, quality, and scalability.

Desired Qualifications

  • Adult solid tumor focus.
  • Multiple regulatory submissions (NDA/BLA/MAA) are strongly preferred.
  • Prior academic appointment in medical oncology with leadership of clinical trials.
  • Experience integrating translational and biomarker strategies into late-stage clinical development.
  • Publication record supporting disease-area credibility.
  • Experience supporting commercialization planning or launch readiness.
  • Exposure to cross-program or portfolio-level development strategy and governance.
  • San Francisco Bay Area location; hybrid work is acceptable.

About the Company

Revolution Medicines

Clinical-stage oncology company developing RAS inhibitors

Revolution Medicines develops precision oncology drugs focused on cancers driven by RAS mutations. Its RAS(ON) inhibitors are small molecules that bind the active form of RAS to block cancer signaling, with candidates like Daraxonrasib (RMC-6236), Elironrasib (RMC-6291), and Zoldonrasib (RMC-9805) advancing in global Phase 3 trials. The company funds its research through collaborations, royalties, and upfront funding, and has not yet marketed a product. Its goal is to bring effective RAS-targeted therapies to patients and advance multiple candidates through late-stage trials toward approval, supported by strong cash reserves.

Company size
1,001-5,000
Company stage
IPO
Headquarters
Redwood City, CA
Founded
2014

Recently Posted Jobs

Explore more opportunities at Revolution Medicines

See more jobs